Inflammatory F2-isoprostane, prostaglandin F2α, pentraxin 3 levels and breast cancer risk: The Swedish Mammography Cohort
- 18 August 2016
- journal article
- research article
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 113, 28-32
Abstract
No abstract availableKeywords
Funding Information
- Conseil Regional d′Auvergne
- Clermont Université, University d′Auvergne
This publication has 30 references indexed in Scilit:
- Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer SpecimenPLOS ONE, 2015
- The Global Burden of Cancer 2013JAMA Oncology, 2015
- PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in CancerCell, 2015
- The Obesity-Inflammation-Eicosanoid Axis in Breast CancerJournal of Mammary Gland Biology and Neoplasia, 2013
- Clinical impact of pentraxin family expression on prognosis of pancreatic carcinomaBritish Journal of Cancer, 2013
- F 2 -Isoprostanes in Human Health and Diseases: From Molecular Mechanisms to Clinical ImplicationsAntioxidants & Redox Signaling, 2008
- Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerBreast Cancer Research, 2007
- Quantification of F2-isoprostanes as a biomarker of oxidative stressNature Protocols, 2007
- Novel cyclooxygenase‐catalyzed bioactive prostaglandin F2α from physiology to new principles in inflammationMedicinal Research Reviews, 2006
- Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and InhibitionPharmacological Reviews, 2004